Mycobacteriophage-mediated gene transfer enables in vitro drug screening and in vivo tracking of Mycobacterium leprae
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2508271122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Lahari Das und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461. Hauptthemen laut MEDLINE: Mycobacterium leprae, Mycobacteriophages, Leprosy, Gene Transfer Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID), NIH HHS.
Abstract (Originalsprache)
Mycobacterium leprae , the causative agent of leprosy, has never been cultured in vitro, posing significant challenges for genetic manipulation and drug discovery. Current antileprosy drug screening methods relying on microscopic count, radiorespirometry, and qPCR are time consuming and require the use of radioactive elements. We demonstrate mycobacteriophage-mediated introduction of foreign DNA using the broad-host range mycobacteriophage TM4 and the application of the luciferase reporter mycobacteriophage (LRM) for drug screening. Mycobacteriophage infection of M. leprae was shown using TM4 expressing the highly sensitive BRET-nanoluciferase-based reporter, GeNL (TM4 ::GeNL ), which enables luminescence measurement for over 72 h. When M. leprae was exposed to rifampicin, dapsone, and Q203 for 24 and 48 h, followed by TM4 ::GeNL infection, the luminescence output decreased in a dose-dependent manner, establishing an in vitro two-day screening assay for drugs. We have also electroporated M. leprae with a ColE1 -integration proficient plasmid expressing GeNL and shown that the transformed leprosy bacilli could be propagated in mice footpads and detected using an in vivo imaging system (IVIS). These findings introduce powerful genetic tools for M. leprae research enabling in vivo tracking and in vitro viability testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461.
- United States Department of Health and Human Services, Health Resources and Services Administration, Health Systems Bureau, National Hansen's Disease Program, Baton Rouge, LA 70816.
ORCID-Profile: Michael Berney, William R Jacobs
Förderung
- NIAID NIH HHS
- HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID)
- NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Das, L., Chen, B., Rajagopalan, S., Vilcheze, C., Mulholland, C. V., Berney, M., Andrews, P. K., Edwards, A., Lahiri, R., & Jacobs, W. R. (2025). Mycobacteriophage-mediated gene transfer enables in vitro drug screening and in vivo tracking of Mycobacterium leprae. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2508271122
Vancouver
Das L, Chen B, Rajagopalan S, Vilcheze C, Mulholland CV, Berney M, et al. Mycobacteriophage-mediated gene transfer enables in vitro drug screening and in vivo tracking of Mycobacterium leprae. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2508271122
BibTeX
@article{Das2025,
author = {Das, Lahari and Chen, Bing and Rajagopalan, Saranathan and Vilcheze, Catherine and Mulholland, Claire V and Berney, Michael and Andrews, Patrick K and Edwards, Ashley and Lahiri, Ramanuj and Jacobs, William R},
title = {Mycobacteriophage-mediated gene transfer enables in vitro drug screening and in vivo tracking of Mycobacterium leprae},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2508271122}
}
EUVIMED